You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 1153 Preclinical activity of C-C chemokine receptor 2 (CCR2)-targeted immune stimulating antibody conjugate (ISAC), motivating clinical testing of TAK-500

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Immune-Stimulants and Immune Modulators
1153 Preclinical activity of C-C chemokine receptor 2 (CCR2)-targeted immune stimulating antibody conjugate (ISAC), motivating clinical testing of TAK-500
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Appleman V, Matsuda A, Ganno M, et al
1153 Preclinical activity of C-C chemokine receptor 2 (CCR2)-targeted immune stimulating antibody conjugate (ISAC), motivating clinical testing of TAK-500
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.1153